Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Reinfections, Persistent Infections, and New Infections After General Population Screening for Chlamydia Trachomatis Infection in The Netherlands

October 21, 2005

The authors conducted a cross-sectional study among a subsample of participants in a population-based screening in urban and rural areas of the Netherlands to determine the rate of new infections, reinfections or persistent infections with Chlamydia trachomatis; to define appropriate screening intervals; and to identify risk factors for reinfection.

A group of 21,000 15- to 29-year-old women and men were offered home-based urine chlamydia testing. One year after the study, a subsample of 299 participants were offered retesting.

The researchers studied the rate of infection with C. trachomatis, using serovar determination to potentially discriminate between new infections and reinfections or persistent infections. They found nine C. trachomatis infections among 187 respondents (4.8 percent confidence interval, 1.7-7.9). Prevalence was 10.4 percent (5 of 48) in previous positives and 2.9 percent (4 of 139) in negatives. Three of 5 repeatedly positive participants were infected with a different C. trachomatis serovar.

Advertisement
"Our study indicates that infected persons found in a systematic, population-based screening should be rescreened within 1 year," the investigators concluded. "Optimal screening intervals still need to be determined."

Back to other news for October 21, 2005

Adapted from:
Sexually Transmitted Diseases
10.05.2005; Vol. 32; No. 10: P. 599-604; Irene K. Veldhuijzen, M.Sc.; Jan E.A.M. Van Bergen, M.D., M.P.H.; Hannelore M. Gotz, M.D., M.P.H.; Christian J.P.A. Hoebe, M.D., Ph.D.; Servaas A. Morre, Ph.D.; Jan Hendrik Richardus, M.D., Ph.D.; for the PILOT CT Study Group


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News

Tools
 

Advertisement